Canaccord Genuity Reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); Lomitapide Potential as Best-in-Class
Tweet
Share
E-mailGet Alerts AEGR Hot Sheet
Price: $1.97 --0%
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Aegerion Pharmaceuticals (NASDAQ: AEGR) price target of $24.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating & price target on lomitapide potential as best-in-class HoFH drug. Lomitapide is AEGR’s Phase 3 drug for HoFH, a rare genetic disease that causes high LDLs. We think lomitapide is the best-in-class HoFH drug in terms of tolerability and efficacy vs. ISIS/SNY’s Phase 3 mipomersen. AEGR will submit lomitapide’s NDA/MAA Q1/12, and we expect FDA approval Q3/12."
"Yesterday competitor ISIS announced another mipo NDA delay; lomitapide, mipo US submissions now both Q1/12. ISIS said the NDA delay was due to a technical glitch. We believe lomitapide’s efficacy and tolerability is superior to mipo. This delay may severely compromise potential first-to-market advantage mipo may have had."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $16.05 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating & price target on lomitapide potential as best-in-class HoFH drug. Lomitapide is AEGR’s Phase 3 drug for HoFH, a rare genetic disease that causes high LDLs. We think lomitapide is the best-in-class HoFH drug in terms of tolerability and efficacy vs. ISIS/SNY’s Phase 3 mipomersen. AEGR will submit lomitapide’s NDA/MAA Q1/12, and we expect FDA approval Q3/12."
"Yesterday competitor ISIS announced another mipo NDA delay; lomitapide, mipo US submissions now both Q1/12. ISIS said the NDA delay was due to a technical glitch. We believe lomitapide’s efficacy and tolerability is superior to mipo. This delay may severely compromise potential first-to-market advantage mipo may have had."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $16.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- UBS Downgrades Klarna (KLAR) to Neutral
- ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
